These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7368942)

  • 1. The pharmacokinetics of dihydroergotamine in the beagle dog after a single intravenous injection and after a continuous intravenous infusion.
    Kanto J; Allonen H; Kleimola T; Mäntylä R
    Acta Pharmacol Toxicol (Copenh); 1980 Apr; 46(4):241-4. PubMed ID: 7368942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection.
    Kanto J; Allonen H; Koski K; Koulu M; Lammintausta R; Mäntylä R; Kleimola T; Siirtola T
    Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):127-30. PubMed ID: 7228454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics of subcutaneous dihydroergotamine with and without a dextran 70 infusion.
    Lindblad B; Abisch E; Bergqvist D
    Eur J Clin Pharmacol; 1983; 24(6):813-8. PubMed ID: 6192998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of dihydroergotamine in the beagle.
    Mäntylä R; Kleimola T; Kanto J
    Int J Clin Pharmacol Biopharm; 1978 Mar; 16(3):124-8. PubMed ID: 649230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dihydroergotamine: pharmacokinetics, pharmacodynamics, and mechanism of venoconstrictor action in beagle dogs.
    Müller-Schweinitzer E; Rosenthaler J
    J Cardiovasc Pharmacol; 1987 Jun; 9(6):686-93. PubMed ID: 2442535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability of dihydroergotamine in man.
    Little PJ; Jennings GL; Skews H; Bobik A
    Br J Clin Pharmacol; 1982 Jun; 13(6):785-90. PubMed ID: 7093108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics and pharmacokinetics of dihydroergotamine (DHE) in conscious beagle dogs.
    Müller-Schweinitzer E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):162-5. PubMed ID: 2459013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of dihydroergotamine following subcutaneous administration in humans.
    Schran HF; Tse FL
    Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):1-4. PubMed ID: 3988387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects.
    Wyss PA; Rosenthaler J; Nüesch E; Aellig WH
    Eur J Clin Pharmacol; 1991; 41(6):597-602. PubMed ID: 1815973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of dihydroergotamine and triacetyloleandomycin in the minipig.
    Martinet M; Kiechel JR
    Eur J Drug Metab Pharmacokinet; 1983; 8(3):261-7. PubMed ID: 6606577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination.
    Schran HF; Bitz DW; DiSerio FJ; Hirsh J
    Thromb Res; 1983 Jul; 31(1):51-67. PubMed ID: 6612697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension.
    Bobik A; Jennings G; Skews H; Esler M; McLean A
    Clin Pharmacol Ther; 1981 Nov; 30(5):673-9. PubMed ID: 6794970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydroergotamine: pharmacokinetics and usefulness in spinal anaesthesia.
    Hilke H; Kanto J; Mäntylä R; Kleimola T; Syvälahti E
    Acta Anaesthesiol Scand; 1978; 22(3):215-20. PubMed ID: 354304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrapulmonary and intravenous administrations of dihydroergotamine mesylate have similar cardiovascular effects in the conscious dog.
    Shrewsbury SB; Stonerook M; Okikawa JK
    Br J Pharmacol; 2008 Jul; 154(6):1254-65. PubMed ID: 18500365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of midazolam in the enflurane-anesthetized dog.
    Hall RI; Szlam F; Hug CC
    J Pharmacokinet Biopharm; 1988 Jun; 16(3):251-62. PubMed ID: 3221325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat.
    Wang Y; Aun R; Tse FL
    Biopharm Drug Dispos; 1998 Dec; 19(9):571-5. PubMed ID: 9872338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of 5,6-dihydro-5-azacytidine (NSC-264880) in the foxhound.
    Malspeis L; Cheng H; Staubus AE
    Invest New Drugs; 1983; 1(1):47-58. PubMed ID: 6206020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection.
    Scully BE; Fu KP; Neu HC
    Am J Med; 1984 Oct; 77(4C):112-6. PubMed ID: 6093511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics and extra-hepatic clearance of remifentanil, a short acting opioid agonist, in male beagle dogs during constant rate infusions.
    Chism JP; Rickert DE
    Drug Metab Dispos; 1996 Jan; 24(1):34-40. PubMed ID: 8825188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of the infusion of alfentanil in man.
    Fragen RJ; Booij LH; Braak GJ; Vree TB; Heykants J; Crul JF
    Br J Anaesth; 1983 Nov; 55(11):1077-81. PubMed ID: 6416281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.